A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Conclusions: The combination of ibrutinib 560 mg daily and durvalumab 10 mg/kg every 2 weeks had an acceptable safety profile. The antitumor activity of the ibrutinib-durvalumab combination was limited in our study population.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Anemia | Breast Cancer | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Pancreas | Pancreatic Cancer | Pneumonia | Study | USA Health